Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 11.
doi: 10.14309/ajg.0000000000003593. Online ahead of print.

Birth Outcomes in Women Who Have Taken Vedolizumab in Pregnancy: Results From the Vedolizumab Pregnancy Exposure Registry

Christina D Chambers  1   2 , Diana L Johnson  1 , Yunjun Luo  1 , Ronghui Xu  2   3 , Margaret P Adam  4 , Stephen R Braddock  5 , Kenneth Lyons Jones  1 ; OTIS Collaborative Research Group
Collaborators, Affiliations

Birth Outcomes in Women Who Have Taken Vedolizumab in Pregnancy: Results From the Vedolizumab Pregnancy Exposure Registry

Christina D Chambers et al. Am J Gastroenterol. .

Abstract

Objectives: There are limited data on the safety of vedolizumab in pregnancy for the treatment of Crohn's disease or ulcerative colitis. Between 2015 and 2022, the Organization of Teratology Information Specialists conducted a prospective, observational pregnancy registry study with 275 pregnant women residing in the United States or Canada.

Methods: Women were enrolled in 1 of 3 cohorts: vedolizumab-exposed (N = 99); disease-matched unexposed to vedolizumab, but treated with another biologic in pregnancy (N = 76); or unexposed with no chronic health conditions (N = 100). Women and their infants were followed up to 1 year postpartum with maternal interviews, questionnaires, medical records abstraction, and a subset of infants who received a physical examination. Study outcomes were major structural birth defects, minor birth defects, pregnancy loss, preterm delivery, prenatal and postnatal growth deficiency, serious or opportunistic infections, malignancies, and developmental milestones.

Results: In the overall registry, 17 of 275 pregnancies (6.2%) were lost to follow-up. Among pregnancies ending in at least 1 live born infant, 7 of 94 (7.4%) in the vedolizumab-exposed cohort compared with 4 of 71 (5.6%) in the disease-matched cohort had a major birth defect (adjusted risk ratio 1.07, 95% confidence interval [CI] 0.33, 3.52). Compared with the disease-matched cohort, women in the vedolizumab-exposed group were not statistically significantly more likely to experience spontaneous abortion (adjusted hazard ratio 1.01, 95% CI 0.17, 5.89). Women in the vedolizumab-exposed group were slightly but not significantly more likely to deliver preterm (adjusted hazard ratio 1.58, 95% CI 0.65, 3.82).

Conclusions: No significant increased risks were noted with vedolizumab exposure for any of the other study outcomes. These data add reassuring evidence in support of the safety of vedolizumab in pregnancy.

Keywords: Crohn's disease; birth defects; pregnancy; registry; safety; ulcerative colitis; vedolizumab.

PubMed Disclaimer

References

    1. Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohn’s Colitis 2016;10(12):1437–44.
    1. Product label. 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125476Orig1s04... . Accessed May 28, 2025.
    1. Mitrova K, Pipek B, Bortlik M, et al. Safety of ustekinumab and vedolizumab during pregnancy – Pregnancy, neonatal, and infant outcome: A prospective multicentre study. J Crohn’s Colitis 2022;16(12):1808–15.
    1. Moens A, van der Woude J, Julsgaard M, et al. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: Results of the European CONCEIVE study. Aliment Pharmacol Ther 2020;51(1):129–38.
    1. Chugh R, Long MD, Jiang Y, et al. Maternal and neonatal outcomes in vedolizumab-and Ustekinumab-exposed pregnancies: Results from the PIANO Registry. Am J Gastroenterol 2024;119(3):468–76.

LinkOut - more resources